Merus N.V.

NASDAQ (USD): Merus N.V. (MRUS)

Last Price

40.19

Today's Change

-0.065 (0.16%)

Day's Change

39.79 - 41.14

Trading Volume

37,020

Overview

Market Cap

2 Billion

Shares Outstanding

68 Million

Avg Volume

618,253

Avg Price (50 Days)

42.09

Avg Price (200 Days)

49.03

PE Ratio

-9.90

EPS

-4.05

Earnings Announcement

26-Feb-2025

Previous Close

40.26

Open

40.76

Day's Range

39.79 - 41.145

Year Range

37.77 - 61.61

Trading Volume

35,435

Price Change Highlight

1 Day Change

-0.42%

5 Day Change

-5.91%

1 Month Change

-0.89%

3 Month Change

-21.28%

6 Month Change

-21.55%

Ytd Change

-5.22%

1 Year Change

-4.59%

3 Year Change

56.48%

5 Year Change

115.42%

10 Year Change

299.30%

Max Change

299.30%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment